loading
Praxis Precision Medicines Inc stock is traded at $173.97, with a volume of 526.68K. It is down -2.27% in the last 24 hours and up +255.26% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$178.01
Open:
$180.93
24h Volume:
526.68K
Relative Volume:
0.68
Market Cap:
$3.66B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-18.97
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
-8.43%
1M Performance:
+255.26%
6M Performance:
+383.25%
1Y Performance:
+146.73%
1-Day Range:
Value
$168.16
$181.00
1-Week Range:
Value
$164.75
$192.96
52-Week Range:
Value
$26.70
$205.89

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name
Name
Praxis Precision Medicines Inc
Name
Phone
617-300-8460
Name
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Name
Employee
82
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
PRAX's Discussions on Twitter

Compare PRAX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PRAX
Praxis Precision Medicines Inc
173.97 4.43B 1.77M -123.74M -95.21M -9.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
421.39 108.36B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
463.43 60.82B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
577.95 61.02B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
817.32 50.01B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
310.81 34.05B 4.56B -176.77M 225.30M -1.7177

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-02-25 Resumed Oppenheimer Outperform
May-07-25 Initiated Chardan Capital Markets Buy
Mar-03-25 Reiterated H.C. Wainwright Buy
Feb-11-25 Initiated Deutsche Bank Buy
Aug-05-24 Initiated Oppenheimer Outperform
Jun-24-24 Initiated Needham Buy
Jun-18-24 Initiated Guggenheim Buy
May-01-24 Initiated Robert W. Baird Outperform
Sep-19-23 Initiated Truist Buy
Jun-06-22 Downgrade Wedbush Outperform → Neutral
Dec-16-21 Initiated H.C. Wainwright Buy
Aug-26-21 Initiated BofA Securities Buy
Apr-26-21 Initiated William Blair Outperform
Nov-11-20 Initiated Wedbush Outperform
Nov-10-20 Initiated Cowen Outperform
Nov-10-20 Initiated Evercore ISI Outperform
Nov-10-20 Initiated Piper Sandler Overweight
View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

pulisher
03:16 AM

How Praxis Precision Medicines Inc. stock valuations compare to rivalsQuarterly Portfolio Summary & Community Consensus Trade Signals - newser.com

03:16 AM
pulisher
03:16 AM

Is Praxis Precision Medicines Inc. stock near bottom after declineEarnings Summary Report & AI Forecast Swing Trade Picks - newser.com

03:16 AM
pulisher
03:07 AM

What institutional flow reveals about Praxis Precision Medicines Inc.Volume Spike & Daily Momentum Trading Reports - newser.com

03:07 AM
pulisher
02:44 AM

How to use Fibonacci retracement on Praxis Precision Medicines Inc.Weekly Stock Recap & Long-Term Growth Plans - newser.com

02:44 AM
pulisher
02:41 AM

Can Praxis Precision Medicines Inc. stock deliver surprise earnings beatJuly 2025 Intraday Action & Daily Entry Point Alerts - newser.com

02:41 AM
pulisher
02:31 AM

Applying big data sentiment scoring on Praxis Precision Medicines Inc.Weekly Earnings Recap & Low Volatility Stock Suggestions - newser.com

02:31 AM
pulisher
Oct 24, 2025

What valuation multiples suggest for Praxis Precision Medicines Inc. stock - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

Is Praxis Precision Medicines Inc a good long term investmentInsider Trading Activity & Affordable Investment Portfolio - earlytimes.in

Oct 24, 2025
pulisher
Oct 24, 2025

Finance Watch: Where There’s A Will, Biopharma Finds A Way - Citeline News & Insights

Oct 24, 2025
pulisher
Oct 24, 2025

Published on: 2025-10-24 12:07:23 - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

Does Praxis Precision Medicines Inc. qualify in momentum factor screening2025 Market Outlook & Low Drawdown Momentum Trade Ideas - newser.com

Oct 24, 2025
pulisher
Oct 23, 2025

Published on: 2025-10-23 02:39:16 - newser.com

Oct 23, 2025
pulisher
Oct 22, 2025

Is Praxis Precision Medicines Worth a Closer Look After 261.8% Surge on Trial Results? - Yahoo Finance

Oct 22, 2025
pulisher
Oct 22, 2025

Praxis Precision Medicines Reports Positive Phase 3 Results for Ulixacaltamide in Essential Tremor - Insider Monkey

Oct 22, 2025
pulisher
Oct 22, 2025

Price momentum metrics for Praxis Precision Medicines Inc. explainedJuly 2025 Short Interest & Safe Capital Growth Trade Ideas - newser.com

Oct 22, 2025
pulisher
Oct 21, 2025

Rapid Rise of PRAX: Essential Tremor Breakthrough - StocksToTrade

Oct 21, 2025
pulisher
Oct 21, 2025

Multi asset correlation models including Praxis Precision Medicines Inc. - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Praxis Precision Medicines, Inc. Announces FDA Type B Meeting for Ulixacaltamide - TradingView

Oct 21, 2025
pulisher
Oct 21, 2025

12 Reddit Stocks That Will Go to the Moon - Insider Monkey

Oct 21, 2025
pulisher
Oct 20, 2025

Wedbush Maintains Praxis Precision Medicines (PRAX) Underperform Recommendation - Nasdaq

Oct 20, 2025
pulisher
Oct 20, 2025

Published on: 2025-10-20 08:35:46 - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Wedbush lifts Praxis Precision Medicines PT; shares down - TradingView

Oct 20, 2025
pulisher
Oct 20, 2025

Largest borrow rate increases among liquid names - TipRanks

Oct 20, 2025
pulisher
Oct 20, 2025

Published on: 2025-10-20 07:35:45 - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Wedbush Boosts Price Target on Praxis Precision Medicines to $73 From $33, Keeps Underperform Rating - MarketScreener

Oct 20, 2025
pulisher
Oct 20, 2025

Praxis Precision Medicines Announces Underwritten Offering - TradingView

Oct 20, 2025
pulisher
Oct 19, 2025

Praxis surges after late-stage trial success for movement disorder therapy - MSN

Oct 19, 2025
pulisher
Oct 19, 2025

Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing. - MSN

Oct 19, 2025

Praxis Precision Medicines Inc Stock (PRAX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$37.26
price up icon 1.11%
$91.28
price up icon 2.21%
$29.89
price up icon 0.07%
$105.66
price up icon 0.87%
$159.66
price down icon 0.29%
biotechnology ONC
$310.81
price up icon 0.25%
Cap:     |  Volume (24h):